ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1779

Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers

Jessica Turnier1, Chioma Madubata2, Christine Goudsmit3, Sean Ferris3, Celine Berthier3, Zilan Zheng4, Sophia Matossian3, Jeff Dvergsten5, Meredyth Wilkinson6, Lucy R Wedderburn7, Gabrielle Morgan8, Lauren Pachman9, Claudia Lalancette3, Stephen Parker3, Andrew Heaton10, J. Michelle Kahlenberg3, Gabriela K Fragiadakis2 and Jessica Neely4, 1University of Michigan, Saline, MI, 2University of California, San Francisco, San Francisco, CA, 3University of Michigan, Ann Arbor, MI, 4UCSF, San Francisco, CA, 5Duke University Hospital, Hillsborough, NC, 6Great Ormond Street Institute of Child Health, London, United Kingdom, 7UCL GOS Institute of Child Health, London, United Kingdom, 8Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 9Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 10Cure JM, Leesburg, VA

Meeting: ACR Convergence 2024

Keywords: Bioinformatics, Muscle Biology, Myositis, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Basic Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children, and it frequently follows a chronic disease course. Treatments are limited secondary to poor understanding of disease pathogenesis. Therefore, we utilized single-nuclear RNA-sequencing as an unbiased approach to uncover tissue-specific cellular drivers and dysregulated biological pathways in JDM muscle.  

Methods: All JDM patients met 2017 EULAR/ACR classification criteria, and 5/6 were treatment-naïve at time of biopsy. Single nuclei were isolated from frozen muscle biopsies of n=6 JDM and n=6 controls (CTL). Samples were multiplexed, and RNA-sequencing was performed using the 10x Genomics Chromium platform. Ambient RNA was removed using SoupX, and Freemuxlet was used for genetic demultiplexing and doublet removal. Sequencing data was integrated using Harmony, and dimensional reduction and clustering was performed using the standard Seurat workflow.  Published cell type specific marker genes were used to annotate cell clusters. Differential gene expression analysis was performed using Model-based Analysis of Single-cell Transcriptomics and cell type proportions were evaluated between JDM and CTL using Wilcoxon rank sum test.

Results: 42,581 nuclei were analyzed, which generated 20 unique clusters (Fig 1A) comprising 12 cell types (Fig 1B & 1C), including multiple myonuclei, endothelial cells (ECs), pericytes, fibroblasts and immune cells. In JDM, increased neuromuscular junction myonuclei and a trend toward fewer type 1 myonuclei (Fig 1D) were noted. While type II myonuclei exhibited predominantly downregulated pathways related to muscle differentiation and function and nitric oxide synthase (NOS) signaling, macrophages, T-cells and ECs displayed increased IFN, cell adhesion and apoptotic signaling. In type II myonuclei, JDM nuclei were overrepresented in cluster 2 compared to cluster 1 (Fig 2A, 2B & 2C), which was enriched for IFN and integrin-linked kinase signaling and class I MHC mediated antigen processing and presentation. NOS1, which is a critical regulator of oxygen delivery, muscle repair and metabolic regulation in type II fibers, was strikingly downregulated in cluster 2 (Fig 2D). IFI44L and ANKRD1, linked to IFN response and EC activation, showed increased expression in cluster 2 (Fig 2D). Given the vasculopathy of JDM, we performed sub-clustering of stromal cells (Fig 3A & 3B) to examine ECs. CTL-predominant ECs in subcluster 4 expressed higher levels of CD36, FLT1 and DACH1 (Fig 3C & 3D), which are key genes in regulation of vascular integrity, angiogenesis and EC migration. JDM-predominant ECs in subcluster 6 expressed a higher IFN signature (MX1 and JAK2) and increased angiopoietin 2 (ANGPT2) (Fig 3C & 3D), which can lead to disruption of vascular integrity.

Conclusion: Single nuclei muscle transcriptomics in JDM highlight that both resident tissue and immune cell types contribute to disease pathogenesis. In particular, type II muscle fibers and ECs demonstrate JDM-specific subpopulations with altered IFN, NOS and angiogenesis signaling. These data generate critical hypotheses to further investigate the vasculopathy, muscle inflammation and fatigue seen clinically in JDM.

Supporting image 1

Figure 1. A, UMAP visualization of clusters identified (Leiden clustering, resolution 0.8). B, UMAP visualization of annotated cell types based on published canonical markers. C, Dot plot highlighting key marker genes utilized for cell type annotations. D, Boxplots comparing cell type proportion differences using Wilcoxon rank sum test between JDM and CTL. A p-value <0.05 was considered statistically significant.

Supporting image 2

Figure 2. A, UMAP visualization of all annotated Leiden clusters (resolution 0.8), including all type II myonuclei clusters. B, UMAP visualization of nuclei colored by disease status, C, Cell type proportion plots comparing differences between type II myonuclei clusters in JDM and CTL (Note: only a subset of the data is shown). D, Violin plots demonstrating cluster-specific expression of NOS1, IFI44L and ANKRD1.

Supporting image 3

Figure 3. A, UMAP visualization highlighting stromal cell subclustering results, with subclusters 4,5,6,9 representing endothelial cells. B, Dot plot highlighting the top 5 marker genes in identified endothelial cell subclusters. C, Cell type proportion plots comparing differences between endothelial cell subclusters in JDM and CTL (Note, only a subset of data from the stromal subclusters is shown). D, Violin plots demonstrating subcluster-specific expression of CD36, FLT1, DACH1, ANGPT2, JAK2, MX1.


Disclosures: J. Turnier: Cabaletta Bio, 1; C. Madubata: None; C. Goudsmit: None; S. Ferris: None; C. Berthier: None; Z. Zheng: None; S. Matossian: None; J. Dvergsten: None; M. Wilkinson: None; L. Wedderburn: Pfizer, 5; G. Morgan: None; L. Pachman: None; C. Lalancette: None; S. Parker: Pfizer, 5; A. Heaton: None; J. Kahlenberg: Amgen, 12, coauthor on publication, AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, 5, Eli Lilly, 2, Gilead, 2, GlaxoSmithKlein(GSK), 2, Janssen, 5; G. Fragiadakis: None; J. Neely: None.

To cite this abstract in AMA style:

Turnier J, Madubata C, Goudsmit C, Ferris S, Berthier C, Zheng Z, Matossian S, Dvergsten J, Wilkinson M, Wedderburn L, Morgan G, Pachman L, Lalancette C, Parker S, Heaton A, Kahlenberg J, Fragiadakis G, Neely J. Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/single-nuclear-rna-sequencing-of-treatment-naive-jdm-muscle-highlights-dysregulated-vascular-integrity-and-angiogenesis-in-endothelial-cells-and-decreased-nitric-oxide-synthase-signaling-in-type-ii-mu/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-nuclear-rna-sequencing-of-treatment-naive-jdm-muscle-highlights-dysregulated-vascular-integrity-and-angiogenesis-in-endothelial-cells-and-decreased-nitric-oxide-synthase-signaling-in-type-ii-mu/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology